Johnson & Johnson (JNJ)
Healthcare · NYSE · US
Price as at 1 Sept 2026, 17:17 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Johnson & Johnson trades at $269.55, which is 38% above the $168.00 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 76 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 29.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
JNJ dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $1.34 | 1 |
| 2003 | $0.925 | 4 |
| 2002 | $0.795 | 4 |
| 2001 | $0.700 | 4 |
| 2000 | $0.620 | 4 |
| 1999 | $0.545 | 4 |
| 1998 | $0.485 | 4 |
| 1997 | $0.425 | 4 |
| 1996 | $0.367 | 4 |
| 1995 | $0.320 | 4 |
| 1994 | $0.283 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
JNJ earnings and analyst estimates
Recommendation mix, 23 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
JNJ passes 6 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
31 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Fisher, Fisher Asset Management, LLC$2.26B · 0.8% of book
- Capital Research Global, Capital Research Global Investors$2.14B · 0.3% of book
- Jeremy Grantham, Grantham, Mayo, Van Otterloo & Co. LLC$1.78B · 4.5% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$738.49M · 0.3% of book
- Marshall Wace, MARSHALL WACE, LLP$581.23M · 0.6% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Johnson & Johnson (JNJ) undervalued?
Against our fair value estimate of $168.00, JNJ at $269.55 is 38% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own JNJ?
31 of the institutions we track reported a position in JNJ in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is JNJ's P/E ratio?
JNJ trades at 29.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Johnson & Johnson (JNJ) pay a dividend?
Yes. Johnson & Johnson yields 2.07% at the current share price. It has paid $1.34 per share over the trailing twelve months. It has paid a dividend in each of the last 42 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its JNJ data?
Fundamentals for JNJ come from company filings and exchange data, as listed on NYSE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Sept 2026, 17:17 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for JNJ, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.